AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2045756 — intervention group
Group type: COMPARATOR
Intervention: Placebo (highly decaffeinated coffee for regular coffee, and china bitter extract for caffeine)
Number of subjects: 15
Study 7299084 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling
Number of subjects: 120
Study 7299084 — intervention group
Group type: COMPARATOR
Intervention: No Counseling (Control)
Number of subjects: 120
Study 30916531 — intervention group
Group type: EXPERIMENTAL
Intervention: Afferent electrical stimulation with mirror therapy
Number of subjects: 30
Study 30916531 — intervention group
Group type: COMPARATOR
Intervention: Sham afferent electrical stimulation with sham mirror therapy
Number of subjects: 30
Study 28658119 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 66
Study 28658119 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 66
Study 25781618 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Number of subjects: 60
Study 25781618 — intervention group
Group type: COMPARATOR
Intervention: Calcitriol
Number of subjects: 60
Study 24106771 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group 1 (TG1, n=282) performing supervised strength training from February to June 2009
Number of subjects: 537
Study 24106771 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group 2 (TG2, n=255) performing supervised strength training from August to December 2009
Number of subjects: 537
Study 24106771 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analyses among those with severe pain (>=3 on a scale of 0-9)
Number of subjects: 537
Study 21354681 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin acetate, 0.3 μg/kg
Number of subjects: 162
Study 21354681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 19383030 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diet (LCD) (800-1000 kcal/day)
Number of subjects: 111
Study 17364459 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg/day
Number of subjects: 0
Study 17364459 — intervention group
Group type: COMPARATOR
Intervention: Finasteride 5 mg/day
Number of subjects: 0
Study 15582073 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03%
Number of subjects: 31
Study 15582073 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 31
Study 11892367 — intervention group
Group type: EXPERIMENTAL
Intervention: Button Pull Group
Number of subjects: 91
Study 11892367 — intervention group
Group type: COMPARATOR
Intervention: Non‐Button Pull Group
Number of subjects: 91
Study 11192135 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg
Number of subjects: 172
Study 11192135 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study 9127332 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG1/IgG clearance ratio
Number of subjects: 34
Study 9127332 — intervention group
Group type: COMPARATOR
Intervention: PA/SA clearance ratio
Number of subjects: 34
Study 9127332 — intervention group
Group type: COMPARATOR
Intervention: IgG1/IgG2 clearance ratio
Number of subjects: 34
Study 1300901 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical drainage after thyroidectomy
Number of subjects: 97
Study 1300901 — intervention group
Group type: COMPARATOR
Intervention: No surgical drainage after thyroidectomy
Number of subjects: 97
Study 3895365 — intervention group
Group type: EXPERIMENTAL
Intervention: Bornaprine 8 mg/die
Number of subjects: 17
Study 3895365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 29804955 — intervention group
Group type: EXPERIMENTAL
Intervention: In-office diagnostic arthroscopy
Number of subjects: 110
Study 29804955 — intervention group
Group type: COMPARATOR
Intervention: Magnetic Resonance Imaging (MRI)
Number of subjects: 110
Study 27594130 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral direct factor Xa inhibitors
Number of subjects: 57497
Study 27594130 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 57497
Study 24779706 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired fasting glucose (IFG)
Number of subjects: 5423
Study 24779706 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 5423
Study 24779706 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity and IFG after excluding underweight individuals (BMI <22 kg/m(2)) and smokers
Number of subjects: 5423
Study 22879450 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-step strategy
Number of subjects: 95
Study 22879450 — intervention group
Group type: COMPARATOR
Intervention: Single-step strategy
Number of subjects: 95
Study 20977339 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16 positive women with intervening negativity for HPV-16 (n=11)
Number of subjects: 86
Study 20977339 — intervention group
Group type: COMPARATOR
Intervention: HPV-16 positive women who consistently tested positive (n=49)
Number of subjects: 86
Study 18568578 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (2-6 mg/day)
Number of subjects: 377
Study 18568578 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5-20 mg/day)
Number of subjects: 377
Study 15890074 — intervention group
Group type: COMPARATOR
Intervention: Single dosage of memantine
Number of subjects: 20
Study 15890074 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascending dosage of memantine over 8 days
Number of subjects: 20
Study 15890074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12381242 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate
Number of subjects: 423
Study 10073852 — intervention group
Group type: EXPERIMENTAL
Intervention: COER-24 verapamil 240 mg titrated to 480 mg at bedtime (n = 173)
Number of subjects: 551
Study 10073852 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg titrated to 10 mg/day (n = 149)
Number of subjects: 551
Study 10073852 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg plus atenolol 50 mg/day in the A.M. (n = 154)
Number of subjects: 551
Study 10073852 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 75)
Number of subjects: 551
Study 7727580 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals aged 16‐20
Number of subjects: 800
Study 7727580 — intervention group
Group type: EXPERIMENTAL
Intervention: Adults aged 21 and over
Number of subjects: 800
Study 7727580 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 800
Study 2390587 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed consent for trial participation
Number of subjects: 3054
Study 2390587 — intervention group
Group type: EXPERIMENTAL
Intervention: Refusal to participate in trials
Number of subjects: 3054
Study 2390587 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastectomy treatment
Number of subjects: 3054
Study 2390587 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusion from trials
Number of subjects: 3054
Study 29178536 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate, high-unsaturated/low-saturated fat diet (LC)
Number of subjects: 115
Study 29178536 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate, low-fat diet (HC)
Number of subjects: 115
Study 26947201 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous rituximab 1600 mg
Number of subjects: 176
Study 26947201 — intervention group
Group type: COMPARATOR
Intervention: Intravenous rituximab 500 mg/m(2)
Number of subjects: 176
Study 24355665 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal influenza vaccination through school-located vaccination program (SLV-I)
Number of subjects: 0
Study 22674243 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg triamcinolone acetonide
Number of subjects: 57
Study 22674243 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 ml 1% procaine HCl
Number of subjects: 57
Study 22674243 — intervention group
Group type: COMPARATOR
Intervention: 1 ml 0.09% saline (placebo)
Number of subjects: 57
Study 19171400 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum apoA-I levels (top tertile)
Number of subjects: 2111
Study 19171400 — intervention group
Group type: COMPARATOR
Intervention: Low serum apoA-I levels (bottom tertile)
Number of subjects: 2111
Study 18637956 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 3
Study 18637956 — intervention group
Group type: EXPERIMENTAL
Intervention: Optokinetic stimulation (OKS)
Number of subjects: 3
Study 18637956 — intervention group
Group type: COMPARATOR
Intervention: Standard exploration training (Control)
Number of subjects: 3
Study 16719158 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant growth hormone (rGH) treatment
Number of subjects: 18
Study 16719158 — intervention group
Group type: COMPARATOR
Intervention: No rGH treatment (Control Group)
Number of subjects: 18
Study 12534607 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone valerate mousse (BVM) applied twice daily for 4 weeks
Number of subjects: 241
Study 12534607 — intervention group
Group type: COMPARATOR
Intervention: Standard therapies (ST) applied once or twice daily for 4 weeks
Number of subjects: 241
Study 11067784 — intervention group
Group type: EXPERIMENTAL
Intervention: White blood cell count 0 to 5x10(9)/L
Number of subjects: 975
Study 11067784 — intervention group
Group type: EXPERIMENTAL
Intervention: White blood cell count 5 to 10x10(9)/L
Number of subjects: 975
Study 11067784 — intervention group
Group type: EXPERIMENTAL
Intervention: White blood cell count 10 to 15x10(9)/L
Number of subjects: 975
Study 11067784 — intervention group
Group type: EXPERIMENTAL
Intervention: White blood cell count >15x10(9)/L
Number of subjects: 975
Study 11067784 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher WBC count
Number of subjects: 975
Study 8860884 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg daily oral progesterone
Number of subjects: 25
Study 8860884 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg daily vaginal progesterone
Number of subjects: 25
Study 8860884 — intervention group
Group type: COMPARATOR
Intervention: Matched placebos
Number of subjects: 25
Study 1292916 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (250 mg, b.i.d.)
Number of subjects: 6
Study 1292916 — intervention group
Group type: EXPERIMENTAL
Intervention: Midecamycin acetate (600 mg, b.i.d.)
Number of subjects: 6
Study 1292916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 6430768 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg ISDN (isosorbide dinitrate) acute administration
Number of subjects: 11
Study 6430768 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg ISDN (isosorbide dinitrate) long-term treatment (40 mg four times daily)
Number of subjects: 11
Study 6430768 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 mg sublingually-administered nitroglycerin (GTN)
Number of subjects: 11
Study 31610718 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet use
Number of subjects: 1343
Study 31610718 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulant
Number of subjects: 1343
Study 31610718 — intervention group
Group type: COMPARATOR
Intervention: Continued warfarin
Number of subjects: 1343
Study 29696423 — intervention group
Group type: EXPERIMENTAL
Intervention: Patterns of interactions among patients, caregivers, and healthcare providers during symptom discussions
Number of subjects: 37
Study 26292778 — intervention group
Group type: COMPARATOR
Intervention: 6 SQ-HDM
Number of subjects: 992
Study 26292778 — intervention group
Group type: COMPARATOR
Intervention: 12 SQ-HDM
Number of subjects: 992
Study 24911223 — intervention group
Group type: EXPERIMENTAL
Intervention: Forgiveness group
Number of subjects: 31
Study 24911223 — intervention group
Group type: EXPERIMENTAL
Intervention: General group
Number of subjects: 31
Study 24911223 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study 22227159 — intervention group
Group type: EXPERIMENTAL
Intervention: High-low mixture group (high training accuracy mixed with low training accuracy, no feedback)
Number of subjects: 36
Study 22227159 — intervention group
Group type: COMPARATOR
Intervention: Low-low mixture group (low training accuracy mixed with low training accuracy, no feedback)
Number of subjects: 36
Study 22227159 — intervention group
Group type: COMPARATOR
Intervention: High accuracy training without feedback
Number of subjects: 36
Study 22227159 — intervention group
Group type: COMPARATOR
Intervention: High and low accuracy training mixed with feedback
Number of subjects: 36
Study 19106238 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 g/d of a dairy drink with 5.8 mg IPP and 4.4 mg VPP
Number of subjects: 162
Study 19106238 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 g/d of a dairy drink with 2.7 mg IPP, 1.9 mg VPP, and 350 mg added K
Number of subjects: 162
Study 19106238 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 19106238 — intervention group
Group type: EXPERIMENTAL
Intervention: LTPs and potassium
Number of subjects: 162
Study 19106238 — intervention group
Group type: EXPERIMENTAL
Intervention: LTPs alone
Number of subjects: 162
Study 17508235 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE using high-kilovoltage (120-kV) DSA and fluoroscopy modes (group B; n = 23)
Number of subjects: 43
Study 17508235 — intervention group
Group type: COMPARATOR
Intervention: TACE using standard-kilovoltage (75- to 90-kV) DSA and fluoroscopy modes (group A; n = 20)
Number of subjects: 43
Study 17508235 — intervention group
Group type: COMPARATOR
Intervention: Comparison between group A and group B
Number of subjects: 43
Study 15834843 — intervention group
Group type: COMPARATOR
Intervention: Nabilone (2 mg/day)
Number of subjects: 6
Study 12075250 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin during the acute phase
Number of subjects: 1218
Study 12075250 — intervention group
Group type: COMPARATOR
Intervention: TIMI risk score for UA/NSTEMI
Number of subjects: 1218
Study 9583393 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous line placement with intradermal saline + benzyl alcohol (0.9%)
Number of subjects: 99
Study 9583393 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous line placement with intradermal lidocaine (1%)
Number of subjects: 99
Study 9583393 — intervention group
Group type: COMPARATOR
Intervention: No anesthesia
Number of subjects: 99
Study 7703876 — intervention group
Group type: EXPERIMENTAL
Intervention: Early discharge program (hospital stay less than 60 hours plus home follow-up by hospital-based nurses)
Number of subjects: 81
Study 7703876 — intervention group
Group type: COMPARATOR
Intervention: Traditional hospital care (hospital stay more than 60 hours and no home follow-up by hospital staff)
Number of subjects: 81
Study 7703876 — intervention group
Group type: EXPERIMENTAL
Intervention: Transferred to early discharge (originally assigned to traditional care)
Number of subjects: 81
Study 2203253 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 mg beta-carotene/d
Number of subjects: 0
Study 2203253 — intervention group
Group type: COMPARATOR
Intervention: Previous photosensitivity-prevention studies
Number of subjects: 0
Study 938116 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position throughout the operative procedure (Group I)
Number of subjects: 64
Study 938116 — intervention group
Group type: EXPERIMENTAL
Intervention: Change to a 15 degrees head down position 15 minutes after a control blood sample (Group II)
Number of subjects: 64
Study 938116 — intervention group
Group type: EXPERIMENTAL
Intervention: Subdiaphragmatic abdominal laparotomy pack without a change in operative position
Number of subjects: 64
Study 30833297 — intervention group
Group type: EXPERIMENTAL
Intervention: Unhealthy snacks (viewed influencers with unhealthy snacks)
Number of subjects: 176
Study 30833297 — intervention group
Group type: COMPARATOR
Intervention: Nonfood products (viewed influencers with nonfood products)
Number of subjects: 176
Study 30833297 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy snacks (viewed influencers with healthy snacks)
Number of subjects: 176
Study 28683834 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconditional cash transfer of US$84 per month for 5 months
Number of subjects: 1200
Study 28683834 — intervention group
Group type: EXPERIMENTAL
Intervention: Single non-food items kit
Number of subjects: 1200
Study 28683834 — intervention group
Group type: EXPERIMENTAL
Intervention: Free piped water
Number of subjects: 1200
Study 28683834 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving the intervention)
Number of subjects: 1200
Study 25450123 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training of progressive muscle relaxation, mental imagery, and phantom exercises 2 times/wk for 4 weeks
Number of subjects: 51
Study 25450123 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy dedicated to the residual limb
Number of subjects: 51
Study 25450123 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training of progressive muscle relaxation, mental imagery, and phantom exercises
Number of subjects: 51
Study 22880843 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 1286
Study 21493732 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (30 + 10 mg)
Number of subjects: 32
Study 21493732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 21493732 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 32
Study 18650512 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir
Number of subjects: 703
Study 18650512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 703
Study 17120844 — intervention group
Group type: EXPERIMENTAL
Intervention: Modal completion display
Number of subjects: 32
Study 17120844 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodal completion display
Number of subjects: 32
Study 12433644 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl (20 microgram/3ml)
Number of subjects: 30
Study 12433644 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fentanyl)
Number of subjects: 30
Study 10328392 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of autologous platelet concentrate (APC) during surgery
Number of subjects: 110
Study 10328392 — intervention group
Group type: COMPARATOR
Intervention: Standardized macular hole surgery without APC
Number of subjects: 110
Study 8598374 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitored group (online observation and intervention)
Number of subjects: 32
Study 8598374 — intervention group
Group type: COMPARATOR
Intervention: Unmonitored group (imaged but not monitored)
Number of subjects: 32
Study 8598374 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitored group
Number of subjects: 32
Study 8598374 — intervention group
Group type: COMPARATOR
Intervention: Unmonitored group
Number of subjects: 32
Study 2046369 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular alcohol content beer (7% alcohol by volume)
Number of subjects: 318
Study 2046369 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-alcohol beer (3% alcohol)
Number of subjects: 318
Study 2046369 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed drinks made with 7/8-oz of distilled spirits
Number of subjects: 318
Study 2046369 — intervention group
Group type: COMPARATOR
Intervention: Low-alcohol conditions (3% beer or mixed drinks)
Number of subjects: 318
Study 2046369 — intervention group
Group type: EXPERIMENTAL
Intervention: Females drinking at the same rate as males
Number of subjects: 318
Study 6888028 — intervention group
Group type: EXPERIMENTAL
Intervention: 35-minute tutorial on how to conduct a discharge interview; n = 181
Number of subjects: 545
Study 6888028 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-minute discharge interview from an investigator; n = 53
Number of subjects: 545
Study 6888028 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (35-minute tutorial and 15-minute discharge interview); n = 63
Number of subjects: 545
Study 6888028 — intervention group
Group type: COMPARATOR
Intervention: Control group; n = 248
Number of subjects: 545
Study 31477163 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive multidisciplinary diabetes mellitus care with patient empowerment
Number of subjects: 0
Study 31477163 — intervention group
Group type: COMPARATOR
Intervention: Routine clinical care
Number of subjects: 0
Study 27896711 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of solifenacin 6 mg plus oral controlled absorption system (OCAS™) formulation of tamsulosin (TOCAS, 0.4 mg)
Number of subjects: 0
Study 27896711 — intervention group
Group type: EXPERIMENTAL
Intervention: TOCAS monotherapy
Number of subjects: 0
Study 27896711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26271567 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathogenetic therapy with antihypoxant reamberin (N=64)
Number of subjects: 232
Study 26271567 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathogenetic therapy with antihypoxant reamberin and hepatoprotector remaxol (N=84)
Number of subjects: 232
Study 26271567 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional support and laparoscopic abdominal sanitation (part of both intervention groups)
Number of subjects: 232
Study 24357857 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% cetrimide
Number of subjects: 26
Study 24357857 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine
Number of subjects: 26
Study 24357857 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine
Number of subjects: 26
Study 23000015 — intervention group
Group type: EXPERIMENTAL
Intervention: RUN task
Number of subjects: 48
Study 23000015 — intervention group
Group type: EXPERIMENTAL
Intervention: EDIT task
Number of subjects: 48
Study 23000015 — intervention group
Group type: COMPARATOR
Intervention: RT task (control)
Number of subjects: 48
Study 19188252 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapamycin treatment prior to exercise
Number of subjects: 0
Study 19188252 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rapamycin)
Number of subjects: 0
Study 19188252 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 17286194 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative informative video
Number of subjects: 100
Study 17286194 — intervention group
Group type: COMPARATOR
Intervention: Control group (no video)
Number of subjects: 100